ABSTRACT
Objective To study the antiviral effects of Pudilan xiaoyan oral liquid on Hep-2 cell models infected with respiratory syncytial virus (RSV), adenoviruses serotype 3 strains (ADV3) in vitro. Methods The cell cytotoxic and inhibition effect of Pudilan xiaoyan oral liquid on RSV or ADV3 were investigated by MTT assay and the inhibitory assay for cytopathic effect (CPE) in Hep-2 cell cultures to detect its antiviral effects. Results The median toxic concentration (TC50) of Pudilan xiaoyan oral liquid on Hep-2 cells was 776.97 mg/L. The median effective concentration (EC50) of inhibiting RSV and ADV3 were 28.08, 28.10 mg/L,whose therapeutic index (TI) were 27.67 and 27.65 respectively. The safety coefficient of Pudilan xiaoyan oral liquid is higher than that of control, ribavirin. Compared with the virus control group, Pudilan xiaoyan oral liquid can obviously produce actions of a dose-dependent relationship to inhibit CPE in Hep-2 cells infected with RSV or ADV3 virus. Conclusions Pudilan xiaoyan oral liquid significantly improves the protection against RSV and ADV3 virus infection in Hep-2 cells. And the inhibition of CPE induced by viruses infection increased with the elevation of higher drug concentration for its antiviral effect augmented in vitro.
ABSTRACT
Objective To investigate the therapeutic effect of the Hubei Wingnut ( Malus hapehensis ) leaf decoction (MHD) against conjunctivitis infected with human simplex virus type I (HSV-1). Methods Malus hupehcnsis decoction was used as the active treatment and ribavirin ( RBV) eye drop was used as the positive control. Both of the Vero cells and rabbit eye conjunctiva were infected with HSV-1. The effect and mechanism of the MHD on viral replication was determined by observing the cytopathic effect ( CPE) . The efficacy of MHD at different doses on the rabbit viral conjunctivitis was examined by pathological changes of eye conjunctiva tissues. Results MHD did not inhibit the proliferation of HSV-1 in vitro. The inflammatory reactions of rabbit viral conjunctivitis caused by HSV-1 were obviously attenuated or disappeared after treatment with MHD at 6 kg·L-1 and 3 kg·L-1 for 7 consecutive days,compared with the negative control of 0. 9% NaCl. The curative rate of MHD at the middle and high doses was 83. 3% and 100. 0%, respectively. Conclusion MHD has the potential for treating eye conjunctivitis caused by HSV-1 by relieving inflammation.
ABSTRACT
[Objective] To determine the effects against human simplex virus type I(HSV-1) and adenovirus type Ⅲ(ADV-3) anti-viral in vitro and in vivo of eye drop prepared by mixed extract of Heartleaf houttuynia and Lonicera japonica.[Methods] By using different numbers of host cells with cytopathic effect(CPE) as the observation index,models of HSV-1 infected Vero cells and ADV-3 infected HeLa cells were established to determine the anti-viral effects in vitro of HLD with different dosages.Rabbit eye conjunctivitis model infected by HSV-1 was established to observe the anti-viral effects in vivo of HLD with different dosages,and the biopsy specimens of pathogenic eye conjunctive tissue were examined by routine pathological methods.In these experiments,a commercial acilovir eye drop(ACV) was used as the control.[Results] The minimum dosages of HLD to completely inhibit the CPEs of HSV-1 and ADV-3,the host cells were 32 mg/ml and 64 mg/ml respectively.After treatment with HLD,the inflammatory reactions of rabbit eye conjunctivitis caused by HSV-1 infection were obviously weak or disappeared.The curative rates of 1,3 and 6 g/ml HLD treating experimental rabbit eye conjunctivitis were 50.0%,83.3% and 100% respectively.Furthermore,the curative effect using 6 g/ml HLD has no significant difference compared to that using ACV drop.[Conclusion] HLD has a certain anti-viral effect in vitro and a stronger anti-viral effect in vivo,indicating the potential of HLD for developing a new drug to prevent or treat viral eye conjunctivitis.
ABSTRACT
OBJECTIVE:To investigate the anti-viral effects of Tongqiao zhike liquid against influenza A virus in vitro.METHODS:The inhibitive effect of Tongqiao zhike liquid administered by different ways against human influenza A virus(H3N2) in vitro and its time-effect relationship were assayed by crystal violet staining assay with ribavirin as positive control.RESULTS:Tongqiao zhike liquid showed a satisfactory comprehensive inhibitory effect against human influenza A virus as well as its proliferation after viral adsorption.It was found that Tongqiao zhike liquid had a weak effect in preventing viral adsorption and it had no direct antiviral effect.The inhibitory effect of low concentration of Tongqiao zhike liquid against influenza A virus weakened time-dependently,while at high concentration its anti-viral ability remained stable.CONCLUSION:Tongqiao zhike liquid has a satisfactory effect against human influenza A virus in vitro.
ABSTRACT
Objective To study the anti-viral effects of Lianhua Qingwen Capsule against influenza A virus in vitro.Methods Under different administration modes,the inhibitory effect of Lianhua Qingwen Capsule on human influenza A virus(H3N2)in vitro and its time-effect relationship were assayed by crystal violet staining assay with ribavirin as positive reference drug.Results Lianhua Qingwen Capsule showed a multi-access effect on anti-human influenza A virus,such as comprehensive inhibition effect,prevention effect on virus adsorption,inhibition on virus proliferation after adsorption and direct killing the virus effect,and the median effective concentrations(EC50)in above-mentioned effects were 0.042,0.031,0.051 and 0.050 mg/mL respectively.Among them,the prevention effect on virus adsorption was the strongest.With the expanding actuation duration of the drug,the inhibitory effect of Lianhua Qingwen Capsule against influenza A virus weakened at low concentration,but no change at high concentration(≥0.031 g/mL).Meanwhile,Lianhua Qingwen Capsule can remarkably decrease the infectivity of influenza A virus.Conclusion Lianhua Qingwen Capsule has an obvious effect against human influenza A virus in vitro.